AffiliationDepartment of Medical Oncology, Paterson Institute of Cancer Research, Christie Hospital NHS Trust, Manchester, UK. Aarmstrong@picr.man.ac.uk
MetadataShow full item record
AbstractObservations that cells of the immune system are able to kill tumor cells both in vitro and in animal models have provided a compelling rationale for pursuit of a strategy whereby immune cells are administered as a therapeutic vaccine to patients with cancer. The successful outcome of this approach depends upon the ability to deliver this therapy in a manner in which a potent immune response is elicited. By harnessing the capacity of dendritic cells that are pivotal in priming the immune response and using gene therapy approaches to optimise the immune response, this may ultimately prove efficacious in the management of human cancer. Promising reports from recent clinical trials suggest that this may well be a realistic goal.
CitationCellular vaccine therapy for cancer. 2002, 1 (3):303-16 Expert Rev Vaccines
JournalExpert Review of Vaccines
- Antitumour immune response and cancer vaccination: the critical role of dendritic cells.
- Authors: Kochman S, Bernard J
- Issue date: 1999
- Dendritic cell-based vaccines in breast and gynaecologic cancer.
- Authors: Hernando JJ, Park TW, Kuhn WC
- Issue date: 2003 Sep-Oct
- Tumor antigen-specific T helper cells in cancer immunity and immunotherapy.
- Authors: Knutson KL, Disis ML
- Issue date: 2005 Aug
- Combinational adenovirus-mediated gene therapy and dendritic cell vaccine in combating well-established tumors.
- Authors: Xia D, Moyana T, Xiang J
- Issue date: 2006 Mar
- Exploiting dendritic cells and natural killer T cells in immunotherapy against malignancies.
- Authors: Fujii S
- Issue date: 2008 May